Ingrezza’s effects on chorea get stronger over time: Trial analysis
Ingrezza's effects on Huntington's-associated chorea appear stronger over time, according to an analysis of the Phase 3 KINECT-HD trial.| Huntington's Disease News
Ingrezza's effects on Huntington's-associated chorea appear stronger over time, according to an analysis of the Phase 3 KINECT-HD trial.| Huntington's Disease News
Ingrezza has been associated with sustained reductions in Huntington's chorea, regardless of concurrent antipsychotic medication use.| Huntington's Disease News
The once-daily oral therapy Ingrezza, from Neurocrine, has now been approved in the U.S. to treat chorea in adults with Huntington’s disease.| Huntington's Disease News
An oral granule formulation of Ingrezza, called Ingrezza Sprinkle, has been granted FDA approval for treating Huntington's-associated chorea.| Huntington's Disease News
Ingrezza Sprinkle is a formulation of oral Ingrezza that's designed to be easier to swallow, with capsule's granules sprinkled on soft foods.| Huntington's Disease News
